mycophenolate sodium / Generic mfg. 
Welcome,         Profile    Billing    Logout  

49 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mycophenolate sodium / Generic mfg.
ACTRN12610000320055: Removal Of Cyclosporine With Everolimus On Inflammation And Vascular Endpoints

Not yet recruiting
4
28
 
Heath Department of Western Australia, Novartis Pharmaceutical Company Pty Ltd, Novartis Pharmaceutical Company Pty Ltd
Cardiovascular risk
 
 
MyERA, ChiCTR-OPC-15006244: Multicenter, prospective study of the effectiveness under immunosuppressive regimens using Myfortic to treat renal transplant recipients from Donation after Circulatory Death in China

Not yet recruiting
4
500
 
Nil
First affiliated hospital, College of Medicine, Zhejiang university; Level of the institution：, sponsored by Novartis
Renal transplantation
 
 
2005-004607-11: Prospective, randomized, long-term study compairing a Neoral (C-0h monitoring)-based steroid-free to an everolimus-myfortic based, calcineurin-inhibitor-free immunosuppressive treatment on graft function and on the long term impact on cardiovascular risk factors after "de novo" kidney transplantation.

Ongoing
4
120
Europe
Myfortic, certican, sodium mycophenolate, Neoral, Capsule*, Myfortic 180 mg, Certican 0.25 mg, Myfortic 360 mg, Certican 0.50 mg, Certican 0.75 mg, Neoral 10 mg, Neoral 25 mg, Neoral 50 mg, Neoral 100 mg
Hopital Erasme
“De novo” renal transplantation
 
 
2013-004934-14: EVEROLIMUS VERSUS MYCOPHENOLIC ACID IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE DIFFERENCES IN RETINAL NEOVASCULARIZATION IN PATIENTS WITH DIABETIC RETINOPATHY EVEROLIMUS VERSUS MYKOFENOLOVÁ KYSELINA U PACIENTŮ PO KOMBINOVANÉ TRANSPLANTACI LEDVINY A SLINIVKY BŘIŠNÍ ZA ÚČELEM ZHODNOCENÍ VÝVOJE NOVOTVORBY CÉV NA SÍTNICI U PACIENTŮ S DIABETICKOU RETINOPATIÍ

Ongoing
4
60
Europe
Certican, Myfortic, Tablet, Certican, Myfortic
Institut klinické a experimentální medicíny, Institut klinické a experimentální medicíny
simultaneous pancreas/kidney allograft transplantation simultánní transplantace pankreatu a ledviny, simultaneous pancreas/kidney allograft transplantation simultánní transplantace pankreatu a ledviny, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]
 
 
2005-001830-34: The use of Myfortic in paediatric patients after liver transplantation

Ongoing
4
10
Europe
Myfortic, ERL080, Myfortic, Myfortic
King\'s College Hospital
Liver transplantation
 
 
2006-004709-24: Mycophenolate sodium (Myfortic®) in the Treatment of Uveitis: a Pilot Study.

Ongoing
4
24
Europe
Myfortic, Neoral, Prednison, Neoral, Neoral
ErasmusMC
Uveitis
 
 
2007-002201-53: An observational study of i)mini-area-under-the-curve (mini-AUC) estimation of exposure to mycophenolic acid (MPA) in heart transplant and lung transplant recipients on mycophenolate mofetil (MMF)or Mycophenolate Sodium (Myfortic) ii) utility of salivary measurements of MPA levels in heart & lung transplant recipients.

Ongoing
4
50
Europe
Myfortic, Cellcept, Myfortic, Cellcept, Myfortic, Cellcept
University Hospital of South Manchester Nhs Foundation Trust
Immunosuppression after heart and lung transplantation
 
 
2006-004773-99: A RANDOMISED CONTROLLED TRIAL COMPARING THE USE OF SIROLIMUS BASED BIPHASIC IMMUNOSUPRESSION WITH MYFORTIC TO ALLOW EARLY CNI WITHDRAWAL IN RENAL TRNASPLANTATION

Ongoing
4
42
Europe
Rapamune, Rapamune, Prograf, Myfortic, Rapamune, Prograf, Myfortic
University Hospitals Leicester
Chronic Allograft Nephropathy
 
 
2007-003649-34: RENAL RESCUE IMMUNOSUPPRESSION FOLLOWING HEART TRANSPLANTATION

Ongoing
4
56
Europe
Mycophenolic acid, Ciclosporin, Tacrolimus, Azathioprine, Mycophenolate mofetil, Myfortic, Neoral, Prograf, Cellcept, Myfortic, Neoral, Prograf, Cellcept
University Hospital of South Manchester NHS Foundation Trust
Renal impairment following heart transplantation
 
 
2013-000766-11: Etude pilote, prospective, multicentrique, randomisée, en ouvert, comparant deux protocoles d’immunosuppression utilisant en traitement d’induction : soit un anticorps monoclonal antirécepteur de l’Interleukine 2 (Simulect®), soit des globulines antilymphocytaires (ATG® Frésénius), associés à une trithérapie Prograf®, Myfortic® et corticoïdes, pour la prévention du rejet chez les adultes transplantés rénaux immunisés de novo.

Ongoing
4
60
Europe
ATG® frésénius, Simulect® (Basiliximab), ATG® frésénius, Simulect® (Basiliximab)
CHU Toulouse, FRESENIUS, NOVARTIS
Prévention du rejet chez les adultes transplantés rénaux
 
 
ChiCTR-IPR-16009202: The prevalence of BK virus infection in De Novo Kidney Transplant Recipients Receiving Mizoribine or Mycophenolic Acid: A Prospective, Randomized, Multicenter Study in China

Recruiting
4
200
 
MZR ;MMF/EC-MPS
Beijing Friendship Hospital, Capital Medical University; Beijing Friendship hospital, Capital Medical University, self-raised
Kidney transplantation
 
 
2021-003089-11: Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING) Tratamiento de las lesiones inflamatorias borderline precoces en pacientes con trasplante renal de bajo riesgo inmunológico (TRAINING)

Not yet recruiting
4
80
Europe
Grafalon, Advagraf, Envarsus, Cellcept, Myfortic, Prednisona, Tacrolimus, Concentrate for solution for infusion, Capsule, Grafalon. Anti-T Lymphocyte Immunoglobulin For Human Use, Rabbit. Intravenous Use. Neovii Biotech Gmbh, Advagraf, Envarsus, Cellcept, Myfortic, Prednisona
Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Instituto de Salud Carlos III
Subclinical inflammation, including borderline lesions (BL), is very common after kidney transplantation (KT), even in low immunological risk patients, and can lead to interstitial fibrosis/tubular atrophy (IFTA) and worsening of renal function with graft loss. The aim of the study is to determine whether the treatment of early BL (3rd month post-KT) with Grafalon decreases the progression of IFTA and the worsening of graft function compared to conventional therapy after two years post-KT. La inflamación subclínica, es muy frecuente tras el trasplante renal (TX), aún en los pacientes de bajo riesgo inmunológico, y puede evolucionar a lesiones crónicas tipo fibrosis intersticial/ atrofia tubular (FIAT) y deterioro de la función renal. El objetivo es determinar si el tratamiento precoz de las lesiones borderline (3 m post-TX) con Grafalon disminuye la progresión de FIAT y deterioro de la función renal comparado con la terapia convencional después de dos años de seguimiento post-TX., The aim of the clinical trial is to study whether treatment of subclinical graft inflammation with grafalon improves kidney function and graft survival. El objetivo del ensayo clínico es estudiar si el tratamiento de la inflamación subclínica del injerto con grafalon mejora la función renal y la supervivencia del injerto., Not possible to specify
 
 
2022-000617-13: prospective, randomized, controlled study evaluating the effect of conversion from tacrolimus treatment to mTor inhibitor-based immunosuppression + tacrolimus to boost conversion to positive SARS-CoV-2 serology after a fourth dose of the vaccine of SARS-CoV-2 mRNA in solid organ transplant recipients who have not previously responded. Un estudio prospectivo, aleatorizado y controlado que evalúa el efecto de la conversión del tratamiento de tacrolimus a la inmunosupresión basada en inhibidores de mTor + tacrolimus para reforzar laconversión a positivo e la serología del SARS-CoV-2 después de una cuarta dosis de la vacuna de ARNm del SARS-CoV-2 en pacientes receptores de trasplante de órgano sólido que no han respondido previamente.

Ongoing
4
50
Europe
Oral solution, Tablet, Capsule, hard, Rapamune, Myfortic, Cellcept
Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR), Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)
Seroconversion is evaluated after changing treatment from tacrolimus to tacrolimus + mTOR inhibitor in solid organ transplant patients who have not responded to the first three doses of the vaccine Se evalua la seroconversión tras el cambio de tratamiento de tacrolimus a tacrolimus + inhibidor de mTOR de los pacientes trasplantados de órgano sólido que no hayan respondido a las tres primeras dosis de la vacuna, Se evalúa si los pacientes crean anticuerpos contra la covid tras cambiar el tratamiento a tacrolimus + imTOR en pacientes trasplantados que no han respondido a las tres primeras dosis de la vacuna It's evaluated if patients create antibodies against covid after changing treatment to tacrolimus + imTOR in transplant patients who have not responded to the first three doses of the vaccine, Body processes [G] - Immune system processes [G12]
 
 
NCT02081755: Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer

Active, not recruiting
4
336
US
Everolimus, Zortress, Afinitor, Tacrolimus, Prograf, Myfortic, Mycophenolic Acid, CellCept, Mycophenolate Mofetil, Imuran, Azathioprine
Baylor Research Institute
Carcinoma, Hepatocellular
06/24
06/24
Application of mycophenolate sodium enteric coated tablets in IgA nephropathy, ChiCTR2200060990: Efficacy and safety of Enteric-coated mycophenolate sodium in IgA nephropathy with activity proliferative lesions

Recruiting
4
102
 
semi hormone combined with Enteric-coated mycophenolate sodium ; semi hormone
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China; The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, China Primary Health Care Fundation
IgA nephropathy
 
 
ChiCTR2200063823: Evaluation of the efficacy and safety of mycophenolate sodium enteric coated tablets versus cyclophosphamide in microscopically induced remission of polyvasculitis: a multicenter, randomized, controlled, open-label prospective non-inferiority clinical trial

Not yet recruiting
4
110
 
Oral mycophenol sodium enteric-coated tablet; cyclophosphamide
Shanxi Medical University Second Hospital; Shanxi Medical University Second Hospital, China Primary Health Care Foundation
Microscopic polyvasculitis
 
 
NCT05872568: Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

Not yet recruiting
4
270
NA
Enteric-Coated Mycophenolate Sodium (EC-MPS)
Zhishui Chen
Kidney Transplant Rejection
12/25
12/25
2009-018174-54: MERIDIAN: A 12-month prospective, open-label, randomized, multicenter,parallel-group study to evaluate the efficacy, safety andtolerability of a Myfortic®-based regimen in the conversion from aCNI to everolimus in de novo transplant recipients of ExpandedCriteria of Donor kidneys

 
3/4
35
Europe
Myfortic, Certican, Sandimmun Neoral, Simulect, ERL080, Myfortic, Certican, Sandimmun Neoral, Simulect, Myfortic, Certican, Sandimmun Neoral, Simulect
Novartis Pharma Services AG, Novartis Farmacéutica, S.A., Novartis Services AG
de novo transplant recipients of Expanded Criteria Donor (ECD) kidneys
 
07/10
ACTRN12611000798965: Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus Nephritis

Recruiting
3
32
 
Royal Brisbane, Royal Brisbane Hospital research Foundation, Novartis Pharmaceuticals Australia
Lupus Nephritis patients
 
 
2008-003540-11: Preventie van ernstige Graft versus Host ziekte na allogene stamcel transplantatie gegeven als immuuntherapie voor patienten met een hematologische ziekte. Een gerandomiseerde fase III studie (HOVON 96 GVHD).

Ongoing
3
500
Europe
Ciclosporine, Myfortic, cyclophosphamide, Capsule, soft, Tablet, Powder for solution for infusion, Concentrate for solution for infusion, Myfortic 180 mg, Myfortic 360 mg
HOVON Foundation, Dutch Cancer Society, HOVON Foundation, Novartis Pharma BV, Novartis Pharma NV, Fresenius, Dutch Cancer society, Hovon Foundation, Novartis pharma BV, Novartis Pharma Belgium
Graft versus Host Disease, Graft versus Host Disease, Diseases [C] - Cancer [C04]
 
 
2004-002973-22: Epidemiological open-label study to evaluate the frequency of helicobacter Pylori infections prior to and after equimolar switch from therapy with MMF to enteric-coated Mycophenolic Acid (MYFORTIC-ERL080) in stable renal transplant patients

Ongoing
3
250
Europe
NA, NA,
AZIENDA UNIVERSITARIA OSPEDALE POLICLINICO UMBERTO I, AZIENDA POLICLINICO UMBERTO I
Profilaxis of rejection in stable renal transplant patients
 
 
2010-018353-36: BeTACTIC Study. Best Therapy After Cardiac Transplantation, the Italian Challenge. A multicenter, prospective, randomized, open-label study to compare the efficacy and safety of Everolimus and Mycophenolate (either mofetil or sodium) in association with Cyclosporine in patients with acute multiple/late rejection, cardiac allograft vasculopathy, renal dysfunction after cardiac transplantation

Ongoing
3
400
Europe
CERTICAN, CELLCEPT, MYFORTIC, CERTICAN, CELLCEPT, MYFORTIC
AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA, GRANDA (A.O. DI RILIEVO NAZIONALE)
Paitents will be enrolled at least one year after heart transplant
 
 
NCT04877288 / 2018-000237-12: A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

Recruiting
3
102
Europe, US
Belatacept, Nulojix, Tacrolimus, Cyclosporine A, Mycophenolate Mofetil, Enteric Coated Mycophenolate Sodium, Corticosteroids
Bristol-Myers Squibb
Renal Allograft Recipients
05/26
01/28
INSTEAD, NCT05385432: Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies

Not yet recruiting
3
244
NA
Rabbit Anti thymocyte globulin (rATG), Maintenance immunosuppressive regimen is the same in experimental and control groups combining tacrolimus, mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS) and steroids, Basiliximab
University Hospital, Tours
Renal Transplant Rejection, Induction Therapy
03/27
03/30
2011-001534-42: Clinical study in which are enrolled patients with malignant hematologic diseases for which there is no indication for allogeneic bone marrow transplantation, and for whom a suitable donor has been identified (fully compatible or partially compatible). Studio clinico nel quale vengono arruolati pazienti affetti da malattie ematologiche maligne, per i quali ci sia indicazione a trapianto di midollo osseo allogenico, e per i quali sia stato individuato un donatore idoneo (totalmente compatibile o parzialmente compatibile).

Ongoing
2
154
Europe
Powder for solution for infusion, Solution for infusion, Tablet, Coated tablet, FLUDARA*EV 5FL 50MG, OVASTAT, ATG FRESENIUS S, MABTHERA*EV 1FL 50ML 500MG, RAPAMUNE*30CPR RIV 2MG, MYFORTIC*250CPR RIV 360MG
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR, MEDAC, FRESENIUS BIOTECH
Pediatric and adult patients (aged from 1 to 70 years) with hematologic malignancies (leukemia, myeloma, lymphoma), candidates for allogeneic transplantation from HLA-identical or HLA-mismatched family is from the register. Pazienti pediatrici e adulti (età compresa da 1 a 70 anni) affetti da patologie maligne ematologiche (leucemia, mieloma, linfoma), candidati a trapianto allogenico da donatore HLA-identico o HLA- mismatched sia familiare che da registro., Pediatric and adult patients (aged 1 to 70 years) suffering from blood cancer (leukemia, lymphoma, etc..) to be undergoing bone marrow transplantation. Pazienti pediatrici e adulti (età compresa da 1 a 70 anni) affetti da tumori del sangue (leucemie, linfomi etc.) che dovranno essere sottoposti a trapianto di midollo osseo., Diseases [C] - Immune System Diseases [C20]
 
 
2005-001827-12: Myfortic ® zur Therapie des Bullösen Pemphigoids. Eine offene monozentrische proof-of-concept Studie

Ongoing
2
10
Europe
Myfortic 180 mg Filmtabletten, Myfortic 180 mg, Myfortic 180 mg
Georg-August-Universität Göttingen, Bereich Humanmedizin
Bullous Pemphigoid
 
 
2005-003070-19: A randomized, multicenter, parallel-group, open-label study to assess the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic®) versus continuation of previous therapy in patients with proliferative lupus nephritis on standard maintenance therapy

Ongoing
2
16
Europe
Myfortic, ERL080A, Myfortic, Myfortic
Novartis Pharma Services AG
lupus nephritis ( as part of the disease \"Systemic Lupus Erythematosus\")
 
 
2009-014997-16: Identification of patients with high probability of not or poorly responding to therapy with mycophenolic acid pro-drugs.

Ongoing
2
150
Europe
Mycophenolate sodium, Myfortic, Myfortic
Medizinische Universität Wien, Abteilung für Nephrologie und Dialyse
Patients with a de novo kidney transplantation
 
 
2005-002207-16: A randomised controlled trial of Myfortic versus Mycophenolate Mofetil in the treatment of multi-system autoimmune disease.

Ongoing
2
40
Europe
Myfortic, Cellcept, Myfortic, Cellcept
Cambridge University Hospitals NHS Foundation Trust
Multi-system autoimmune diseases including vasculitis and systemic lupus erythematosus (SLE)
 
 
NCT04195633: Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Recruiting
2
60
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cyclosporine, 27-400, Ciclosporin, CsA, Cyclosporin, Cyclosporin A, Cyclosporine Modified, Gengraf, Neoral, OL 27-400, Sandimmune, SangCya, Filgrastim, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Filgrastim-aafi, Nivestym, Fludarabine, Fluradosa, Mycophenolate Mofetil, Cellcept, MMF, Mycophenolate Sodium, ERL 080, ERL 080A, Socium Mycophenolate, Total-Body Irradiation, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation, SCT_TBI, Treosulfan, 1,2,3, 4-Butanetetrol, 1,4-dimethanesulfonate, [R-(R*,S*)]-, Dihydroxybusulfan, Ovastat, Treosulphan, Tresulfon
Fred Hutchinson Cancer Center, medac GmbH
Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma, Anaplastic Large Cell Lymphoma, Burkitt Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma
12/24
12/26
NCT02566304: Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Active, not recruiting
2
35
US
Fludarabine, Fludarabine phosphate, Fludara, Total-Body Irradiation, T Cell-Depleted Donor Lymphocyte Infusion, Cyclophosphamide, Endoxan, Cytoxan, Neosar, Procytox, Revimmune, Cycloblastin, Cytophosphane, CP, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Tacrolimus, FK-506, Fujimycin, Prograf, Advograf, Protopic, Mycophenolate mofetil, Mycophenolic acid, MMF, CellCept, Myfortic, Laboratory Biomarker Analysis
Sidney Kimmel Cancer Center at Thomas Jefferson University
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Aplastic Anemia, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Malignant Neoplasm, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
02/24
02/24
NCT06478017: Belatacept in Heart Transplantation

Not yet recruiting
2
66
US
Belatacept, NULOJIX, Tacrolimus, Prograf, Mycophenolate Mofetil/Sodium, CellCept, Myfortic, Prednisone
National Institute of Allergy and Infectious Diseases (NIAID)
Heart Transplant
01/28
01/28
NCT03644667: Tocilizumab in Cardiac Transplantation

Active, not recruiting
2
385
US
tocilizumab, Actemra®, Placebo, Placebo for tocilizumab, Placebo for Actemra®, Standard of Care Triple IS, calcineurin inhibitor: (tacrolimus (Prograf ®)), anti-proliferative treatment: (mycophenolate mofetil ),, MMF, CellCept®, Myfortic®, enteric-coated mycophenolate sodium, steroids: methylprednisolone/prednisone
National Institute of Allergy and Infectious Diseases (NIAID), PPD
Heart Transplant
04/25
04/25
NCT02782546: Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

Recruiting
2
60
US
Graft cell infusion, HCT, Tacrolimus, Prograf, Mycophenolate mofetil, CellCept, Myfortic, G-CSF, Granulocyte-colony stimulating factor, CIML NK cell infusion, ALT-803, Leukapheresis
Washington University School of Medicine, National Institutes of Health (NIH), The V Foundation for Cancer Research, National Cancer Institute (NCI), ImmunityBio, Inc.
Acute Myeloid Leukemia
01/26
01/26
NCT00882895: Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Active, not recruiting
2
18
US
Stem cell infusion, TLI, Anti-thymocyte globulin, ATG, Atgam, Thymoglobulin, Solumedrol, Medrol, Solu-Medrol, Tacrolimus, FK-506, Prograf, Advagraf, Protopic, Mycophenolate mofetil, MMF, CellCept, Myfortic
Washington University School of Medicine
Lymphoma, Non-Hodgkin
06/28
06/28
TASK, NCT02711826: Treg Therapy in Subclinical Inflammation in Kidney Transplantation

Completed
1/2
14
US
Polyclonal Regulatory T Cells, Polyclonal Tregs, polyTregs, Everolimus, Zortress, Tacrolimus, FK-506, FR-900506, Prograf, Mycophenolate mofetil, Cellcept, MMF, Mycophenolic acid, Myfortic, MPA, Acetaminophen, Tylenol, Diphenhydramine, Benadryl, Biopsy, Kidney, Kidney Biopsy, Blood Draw, Phlebotomy, Venipuncture, Leukapheresis, leukocytapheresis, IS regimen conversion, Everolimus Conversion
National Institute of Allergy and Infectious Diseases (NIAID), Clinical Trials in Organ Transplantation
Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant, Living Kidney Donor
08/23
08/23
ERPL-CTP-001, NCT06394232: Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.

Recruiting
1/2
54
RoW
Eyecyte-RPE™, Subretinal Injection, Oral Tacrolimus, Oral Mycophenolate Sodium
Eyestem Research Pvt. Ltd.
Retinal Disease, Macular Degeneration, Age-Related Macular Degeneration, Geographic Atrophy, Eye Diseases
10/24
12/30
ChiCTR-IPR-14005509: Effect of Enteric-coated mycophenolate sodium on post-transplant infection rate after renal transplantation compared with Mycophenolate mofetil

Recruiting
1
101
 
Patients underwent treatment with a standard tripletherapy immunosuppressant protocol consisting of tacrolimus, EC-MPS, and prednisone ;Patients underwent treatment with a standard tripletherapy immunosuppressant protocol consisting of tacrolimus, MMF, and prednisone
Qilu Hospital of Shandong University; Level of the institution：, The 2012 annual organ transplantation research project of International exchange and cooperation center of the Ministry of health
End-stage renal disease
 
 
NCT04473911: Haplo Peripheral Blood Sct In GVHD Prevention

Active, not recruiting
1
25
US
FLUDARABINE, Fludara®, CYCLOPHOSPHAMIDE, Cytoxan®, Neosar®, TBI, Melphalan, Alkeran®, L-PAM, L-Sarcolysin, Phenylalanine Mustard, Sirolimus, Rapamune, Mycophenolate mofetil, CellCept, Myfortic, RGI-2001
Zachariah Michael DeFilipp, Regimmune Corporation
GVHD, AML, ALL, MDS, MPN, CMML, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Blood Stem Cell Transplant Failure, Graft Vs Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder, Chronic Myelomonocytic Leukemia, Chemosensitive Hodgkin Lymphoma
10/23
10/24
NCT04375631: CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Recruiting
1
120
US
Cladribine, 2-CdA, 2CDA, CdA, Cladribina, Leustat, Leustatin, Leustatine, RWJ-26251, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cyclosporine, 27-400, Ciclosporin, CsA, Cyclosporin, Cyclosporin A, Cyclosporine Modified, Gengraf, Neoral, OL 27-400, Sandimmune, SangCya, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Filgrastim, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Nivestym, Filgrastim-aafi, Filgrastim-ayow, Releuko, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Transplantation, HSCT, Stem Cell Transplant, stem cell transplantation, Hematopoietic Stem Cell Infusion, Mitoxantrone, Dihydroxyanthracenedione, Mitozantrone, Mycophenolate Mofetil, Cellcept, MMF, Mycophenolate Sodium, ERL 080, ERL 080A, Socium Mycophenolate, Total-Body Irradiation, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation, SCT_TBI, Idarubicin, 4-DMDR, Fludarabine, Fluradosa, 9-Beta-D-arabinofuranosyl-2-fluoroadenine, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Echocardiography, EC, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Undifferentiated Leukemia
12/25
12/27
NCT03249831: A Blood Stem Cell Transplant for Sickle Cell Disease

Active, not recruiting
1
3
US
Cyclophosphamide, Cytoxan, Pentostatin, NIPENT, Rabbit anti-thymocyte globulin, Rabbit ATG, Thymoglobulin, Tacrolimus, PROGRAF®, Mycophenolate mofetil, MMF, CellCept®, Myfortic, CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant, CD4+ T-cell depleted HaploHCT, CD4+ T-cell depleted hematopoietic progenitor cell (HPC) product
City of Hope Medical Center, California Institute for Regenerative Medicine (CIRM)
Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies, Thalassemia, Anemia, Sickle Cell
11/24
11/24
TEACH, NCT03504241: Tolerance by Engaging Antigen During Cellular Homeostasis

Active, not recruiting
1
8
US
Donor-derived Mesenchymal Stromal Cells, Donor-derived MSCs, human bone marrow derived MSCs, hBM-MSC, EPIC-MSC-ITN2015-IVF-0X, alemtuzumab, Campath®, Lemtrada®, belatacept, Nulojix®, LEA29Y, sirolimus, Rapamune®, mycophenolate mofetil, CellCept®, mycophenolate acid, Myfortic®, prednisone, corticosteroid
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), PPD, Rho Federal Systems Division, Inc.
Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
12/27
12/29
NCT01309022: Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)

No Longer Available
N/A
US
Sirolimus, Rapamune®, Tacrolimus, Prograf®, Mycophenolate mofetil, MMF, CellCept, Mycophenolic acid, Myfortic®
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN)
Diabetes Mellitus, Type 1
 
 
OnceDaily, NCT02426502: Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients

Active, not recruiting
N/A
76
Canada
Conversion to Advagraf, Prograf, Cyclosporine (Neoral), Advagraf, conversion of non-immunosuppressant drugs to once daily, anti-hypertensive medications, non-immunosuppressant drugs, Conversion to once daily MPA, Mycophenolate Mofetil, Myfortic, Azathioprine, Prednisone
University of British Columbia, Astellas Pharma Canada, Inc.
End-Stage Renal Disease
08/22
12/24
ChiCTR2200062325: Bioequvalence research of Mycophenolate Sodium Enteric-coated Tablets in healthy people

Not yet recruiting
N/A
68
 
Mycophenolate Sodium Enteric-coated Tablets ;Mycophenolate Sodium Enteric-coated Tablets
Yue Bei People's Hospital; Yue Bei People's Hospital, Changsha Duxact Biotech Co.
Healthy people
 
 
NCT06044558: Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics

Completed
N/A
507
RoW
Combined with voriconazole, tacrolimus, methylprednisolone sodium succinate, mycophenolate sodium, Combined with caspofungin, Tacrolimus-alone treatment
LI YAN
Kidney Transplant Patients
01/23
06/23
ChiCTR2300075403: Pharmacokinetics and Bioequivalence study of mycophenolate sodium enteric-coated tablets in healthy Chinese volunteers

Completed
N/A
60
 
In the fasting state, taking the test formulation in first period and then taking the reference formulation in second period, and taking the test formulation in third period and then taking the reference formulation in fouth period. ;In the fasting state, taking the reference formulation in first period and then taking the test formulation in second period, and taking the reference formulation in third period and then taking the test formulation in fouth period. ;In the fed state, taking the test formulation in first period and then taking the reference formulation in second period, and taking the test formulation in third period and then taking the reference formulation in fouth period. ;In the fed state, taking the reference formulation in first period and then taking the test formulation in second period, and taking the reference formulation in third period and then taking the test formulation in fouth period.
Deyang People's Hospital; Zhejiang Meidishen Biopharmaceutical Co., Ltd, Zhejiang Meidishen Biopharmaceutical Co., Ltd
Prevention of acute rejection in adult patients receiving allogeneic kidney transplantation
 
 
NCT04645589: Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis

Recruiting
N/A
64
RoW
Myfortic, Mycophenolate sodium
Novartis Pharmaceuticals
Lupus Nephritis
07/25
07/25
NCT01999361: Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

Recruiting
N/A
18
US
Myfortic, mycophenolic acid
Rodolfo Alejandro
Type 1 Diabetes Mellitus
01/25
12/26

Download Options